

13<sup>th</sup> February, 2026

The Deputy Manager,  
Department of Corporate Services,  
BSE Limited,  
P.J. Towers, Dalal Street, Fort,  
Mumbai - 400001.

Scrip Code: 507486 (BSE)

Dear Sir,

**Subject: Outcome of Board Meeting held on February 13, 2026**

We hereby inform you that, in compliance with Regulation 30 read with Schedule III, Regulation 33, Regulation 42 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of Caprolactam Chemicals Limited ("the Company"), at their Meeting held today viz. February 13<sup>th</sup>, 2026, has inter-alia, approved the following:

1. Unaudited Standalone Financial Results for the quarter ended December 31, 2025: Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Statement of Unaudited Standalone Financial Results for the quarter ended December 31, 2025 along with Limited Review Report submitted by the Statutory Auditors of the Company. The above financial results were upon recommendation of the Audit Committee approved by the Board of Directors at its meeting held on February 13<sup>th</sup>, 2026.

The meeting of the Board of Directors of the Company commenced at 4.00 p.m. and concluded at **4:50** p.m.

Other Items approved in the Board meeting:


2. Revision in Remuneration of Mr. Siddharth Shankarlal Bhanushali (DIN: 01721586) the Chief Financial Officer cum Whole-Time Director of the Company.
3. Revision in Remuneration of the Ms. Zaver Shankarlal Bhanushali (DIN: 00663374) Managing Director of the Company.
4. Related Party Transaction with Ms. Shital Bhanushali (PAN: ATYPB4439L) with regards to Leasing of Property.
5. Revision in Consultancy Fees Payable by the Company to Related Party - Mr. Shankar Bhanushali.

Kindly take the same on your record.

We request you to inform your members accordingly.

Thanking you.  
Yours faithfully,

For Caprolactam Chemicals Limited



Zaver Shankarlal Bhanushali  
Managing Director  
DIN: 00663374





**PULINDRA PATEL & CO.**  
**CHARTERED ACCOUNTANTS**

Office No. A-1004, Paras Business Center, Kasturba Road No.1, Near Borivali Station East, Borivali East, Mumbai – 400 066,  
Office (Tel) +022-28069664,022-22056233,022-68844594,+91-9322268243,Office (M) +91-9619908533  
Email : caoffice@pulindrapatel.com, pulindra\_patel@hotmail.com

**Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
The Board of Directors,  
Caprolactam Chemicals Limited  
Plot No. B-31, M.I.D.C.- Mahad,  
Taluka – Mahad,  
Dist Raigad – 402302.

We have reviewed the quarterly unaudited standalone financial results of **M/S.CAPROLACTAM CHEMICALS LIMITED** (the company) for the, Quarter ended December 31, 2025 and year to date results for the period from 1<sup>st</sup> April, 2025 to 31<sup>st</sup> December, 2025 (the Statement”) together with the Unaudited Statement of Assets and Liabilities, Unaudited Statement of Cash Flows attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 as amended ( “Listing Regulations”).

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the Statement in accordance with the standard on Review Engagement (SRE) 2410 ‘Review of Interim Financial Information performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial



data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PULINDRA PATEL & CO.  
CHARTERED ACCOUNTANTS  
FIRM REGN. NO. 115187W


*Pulindra M. Patel*

PULINDRA PATEL  
MEMBERSHIP No. 048991  
UDIN: 26048991WTXSXD7040



Place: Mumbai  
Date : 13<sup>th</sup> February, 2026

**Caprolactam Chemicals Limited**  
CIN No. L24110MH1988PLC049683  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025**

PART I		(Rs. In Lakhs)					
		Quarter Ended			Nine Months Ended		Year Ended
		(Unaudited)			(Unaudited)		(Audited)
PARTICULARS		31.12.2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
<b>1</b>	<b>Revenue From Operation</b>						
	Revenue from Operations	256.31	236.27	229.38	749.05	513.10	673.96
	Other Income	0.09	2.23	0.58	2.41	0.79	0.96
	<b>Total Income</b>	<b>256.40</b>	<b>238.50</b>	<b>229.96</b>	<b>751.46</b>	<b>513.89</b>	<b>674.92</b>
<b>2</b>	<b>Expenses</b>						
(a)	Cost of materials consumed	10.80	23.47	48.93	63.67	80.89	53.22
(b)	Purchase of stock - In trade	4.03	1.44	7.49	10.40	45.70	84.64
(c)	Change in inventories of Finished goods, work-in-progress and stock-intrade	-	-	11.82	3.75	-3.75	-3.75
(d)	Employee benefits expenses	11.80	11.27	8.04	34.34	26.88	37.09
(e)	Finance Costs	17.69	18.74	16.83	54.68	45.24	62.86
(f)	Depreciation, depletion and amortisation expenses	40.53	39.09	40.36	117.64	117.63	158.85
(g)	Other expenses	118.98	134.16	105.83	355.53	233.73	350.38
	<b>Total Expenses</b>	<b>203.83</b>	<b>228.17</b>	<b>239.30</b>	<b>640.01</b>	<b>546.31</b>	<b>743.29</b>
<b>3</b>	<b>Profit / (Loss) before tax (1-2)</b>	<b>52.57</b>	<b>10.33</b>	<b>-9.34</b>	<b>111.45</b>	<b>-32.42</b>	<b>-68.37</b>
<b>4</b>	<b>Tax Expense</b>						
	Current tax	8.21	-3.05	-	17.39	-	-
	Deferred tax	0.81	0.82	-6.17	1.74	-6.61	2.50
	<b>Total Tax Expenses</b>	<b>9.02</b>	<b>-2.23</b>	<b>-6.17</b>	<b>19.13</b>	<b>-6.61</b>	<b>2.50</b>
<b>5</b>	<b>Total Profit/(loss) After Tax (3-4)</b>	<b>43.55</b>	<b>12.56</b>	<b>-3.17</b>	<b>92.32</b>	<b>-25.81</b>	<b>-70.87</b>
<b>6</b>	<b>Other Comprehensive Income (OCI)</b>						
	a) Items That Will Not Be Reclassified To Profit or Loss			-			-0.96
	b) Items That Will Be Reclassified To Profit or Loss			-			-
<b>7</b>	<b>Total Comprehensive Income/(Loss) for the period (5+6)</b>	<b>43.55</b>	<b>12.56</b>	<b>-3.17</b>	<b>92.32</b>	<b>-25.81</b>	<b>-71.83</b>
<b>8</b>	<b>Details of equity share capital</b>						
<b>9</b>	<b>Paid-up equity share capital</b>	<b>460.00</b>	<b>460.00</b>	<b>460.00</b>	<b>460.00</b>	<b>460.00</b>	<b>460.00</b>
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
<b>10</b>	<b>Other Equity</b>						
<b>11</b>	<b>Earnings per share</b>						
<b>12</b>	<b>Earnings per equity share Rs.</b>						
	Basic	0.95	0.27	-0.07	2.01	-0.56	-1.54
	Diluted	0.95	0.27	-0.07	2.01	-0.56	-1.54
<b>13</b>	<b>Nominal value of share</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>
<b>Disclosure of notes on finance results</b>							
1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th February, 2026 and have been subjected to limited review by the Auditors.							
2) These financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.							
3) The Standalone results of the company are available on the company's website <a href="http://caprolactam.co.in/">http://caprolactam.co.in/</a> and also available on the websites of the BSE Ltd.							
4) The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from 21st November, 2025. The corresponding all supporting rules under these codes are yet to be notified.							
The company is in the process of evaluating the full impact of these new labour codes announced. The Company is in the process of evaluating other possible impacts including for contract workforce. However, management is of the view that impact, if any, is unlikely to be material.							
5) Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary. Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary.							
6) The figures in Rs. Lakhs are rounded off to Two Decimals							
Place: Mahad		 <b>MANAGING DIRECTOR OF THE BOARD OF DIRECTORS</b>  <b>Mrs. Zaver S Bhanushali</b> Managing Director <b>DIN- 00663374</b>					
Date: 13/02/2026							